IgA Nephropathy

Nephrology·MeSH: Glomerulonephritis, IGA

Prevalence

25.0 / 100K

Incidence

2.5 / 100K/yr

21 drugs in development·14 companies·16 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
FILSPARI®	Travere Therapeutics, Inc. (TVTX)

Phase 3(5)

Drug	Company
atrasentan	CHINOOK THERAPEUTICS, INC. (KDNY)
bion-1301	NOVARTIS AG (NVSEF)
bion-1301	Novartis AG (NVS)
lnp023	Novartis AG (NVS)
oms721	OMEROS CORP (OMER)

Phase 2(8)

Drug	Company
adx-097	Q32 Bio Inc. (QTTB)
AKB-097	Akebia Therapeutics, Inc. (AKBA)
Atacicept	Vera Therapeutics, Inc. (VERA)
atrasentan	Novartis AG (NVS)
blisibimod	ANTHERA PHARMACEUTICALS INC (ANTH)
jade101	Jade Biosciences, Inc. (JBIO)
xh-s003	INFINITY PHARMACEUTICALS, INC. (INFI)
zigakibart	Novartis AG (NVS)

Phase 1(2)

Drug	Company
ARO-CFB	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
BHV-1400	Biohaven Ltd. (BHVN)

Phase 1/Phase 2(3)

Drug	Company
bion-1301	CHINOOK THERAPEUTICS, INC. (KDNY)
bion-1301 multiple doses	Novartis AG (NVS)
bion-1301 single dose	Novartis AG (NVS)

Phase 4(2)

Drug	Company
atrasentan	NOVARTIS AG (NVSEF)
TARPEYO®	Calliditas Therapeutics AB (CALT)

BioSniper tracks 21 drugs in development for IgA Nephropathy across 14 companies.

There are 16 clinical trials targeting IgA Nephropathy tracked by BioSniper.

The estimated prevalence of IgA Nephropathy is approximately 25.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.